Ifinatamab Deruxtecan in SCLC
Subgroup Analysis of Patients With Refractory SCLC From a Phase I/II Trial Evaluating the Novel ADC Ifinatamab Deruxtecan

Released: September 13, 2023

Activity

Progress
1
Course Completed